Granted Patent
B2
US 12,332,245 · App. 17/664,006 · Granted Jun 17, 2025
Cancer biomarkers and methods of use thereof
Inventors:
Thea D. Tlsty (San Francisco, CA); Hal K. Berman (Toronto, CA); Mona L. Gauthier (Toronto, CA); Bob Y. Liu (San Francisco, CA); Colleen A. Fordyce (San Francisco, CA); Curtis R. Pickering (San Francisco, CA); Paul A. Reynolds (San Francisco, CA); Nancy Dumont (San Francisco, CA); Geoffrey M. Benton (San Francisco, CA)
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention provides detection methods for detecting a pre-cancerous epithelial cell signature. The present invention further provides reagents for use in the detection methods. A subject detection method is useful in various imaging, diagnostic, prognostic, and patient monitoring methods, which are also provided.
Claims (37)
1. A method of treating breast cancer in a subject, comprising:
collecting a biological sample from a subject having at least one of ductal carcinoma in situ (DCIS) or atypical ductal hyperplasias (ADH);
detecting a mammary epithelial cell signature for the biological sample by contacting the biological sample with a composition comprising at least three detection reagents, wherein the at least three detection reagents comprise:
a first detection reagent that binds to a first mammary epithelial cell structure, the first mammary epithelial cell structure selected from the group consisting of a p16 protein and an mRNA encoding the p16 protein, wherein the first detection reagent comprises an antibody, or a nucleic acid;
a second detection reagent that binds to a second mammary epithelial cell structure, the second mammary epithelial cell structure selected from the group consisting of a Ki67 protein and an mRNA encoding the Ki67 protein, wherein the second detection reagent comprises an antibody, or a nucleic acid; and
a third detection reagent that binds to a third mammary epithelial cell structure, the third mammary epithelial cell structure selected from the group consisting of a COX-2 protein and an mRNA encoding the COX-2 protein, wherein the third detection reagent comprises an antibody, or a nucleic acid,
wherein each of the first, second and third detection reagents comprises a detectable label, and wherein the detectable labels of the first, second, and third detection reagents are different from each other;
upon determining that the detected mammary epithelial cell signature comprises an elevated level of expression of each of the first, second and third mammary epithelial cell structures compared to respective control levels of expression of the first, second and third mammary epithelial cell structures, providing a treatment to the subject, wherein the treatment comprises:
a) lumpectomy with an additional therapy; or
b) mastectomy.
2. The method of claim 1 , wherein the detectable label is selected from gold, a fluorescent protein, a chromogenic protein, a fluorescent dye, an enzyme, a biotin, a radioisotope and any combinations thereof.
3. The method of claim 1 , wherein the biological sample is selected from the group consisting of a living cell, a dead cell, any non-cellular liquid samples comprising nipple aspirate fluid, and a lavage sample, and any combinations thereof.
4. The method of claim 1 , wherein the biological sample comprises a mammary tissue sample.
5. The method of claim 1 , wherein the first detection reagent comprises an antibody that binds to the p16 protein, and wherein the second detection reagent comprises an antibody that binds to the Ki67 protein.
6. The method of claim 1 , wherein the first detection reagent comprises an antibody that binds to the p16 protein, wherein the second detection reagent comprises an antibody that binds to the Ki67 protein, and wherein the third detection reagent comprises an antibody that binds to the COX-2 protein.
7. The method of claim 1 , wherein the first detection reagent comprises an antibody that binds to the p16 protein, and wherein the third detection reagent comprises an antibody that binds to the COX-2 protein.
8. The method of claim 1 , wherein the second detection reagent comprises an antibody that binds to the Ki67 protein, and wherein the third detection reagent comprises an antibody that binds to the COX-2 protein.
9. The method of claim 1 , wherein the at least three detection reagents consist essentially of the first, second and third detection reagents.
10. The method of claim 1 , wherein the at least three detection reagents consist of the first, second and third detection reagents.
11. A method of treating breast cancer in a subject, comprising:
collecting a biological sample from a subject having at least one of ductal carcinoma in situ (DCIS) or atypical ductal hyperplasias (ADH);
detecting a mammary epithelial cell signature for the biological sample by contacting the biological sample with a composition comprising at least three detection reagents, wherein the at least three detection reagents, comprise:
a first detection reagent that binds to a first mammary epithelial cell structure, the first mammary epithelial cell structure selected from the group consisting of a p16 protein and an mRNA encoding the p16 protein, wherein the first detection reagent comprises an antibody, or a nucleic acid;
a second detection reagent that binds to a second mammary epithelial cell structure, the second mammary epithelial cell structure selected from the group consisting of a Ki67 protein and an mRNA encoding the Ki67 protein, wherein the second detection reagent comprises an antibody, or a nucleic acid; and
a third detection reagent that binds to a third mammary epithelial cell structure, the third mammary epithelial cell structure selected from the group consisting of a COX-2 protein and an mRNA encoding the COX-2 protein, wherein the third detection reagent comprises an antibody, or a nucleic acid,
wherein each of the first, second and third detection reagents comprises a detectable label, and wherein the detectable labels of the first, second, and third detection reagents are different from each other; and
treating the subject with lumpectomy without additional therapy upon determining that the detected mammary epithelial cell signature comprises a reduced level of expression of at least one of the first, second and third mammary epithelial cell structures compared to respective control levels of expression of the first, second and third mammary epithelial cell structures.
12. The method of claim 11 , wherein the detectable label is selected from gold, a fluorescent protein, a chromogenic protein, a fluorescent dye, an enzyme, a biotin, a radioisotope and any combinations thereof.
13. The method of claim 11 , wherein the biological sample is selected from the group consisting of a living cell, a dead cell, any non-cellular liquid samples comprising nipple aspirate fluid, and a lavage sample, and any combinations thereof.
14. The method of claim 11 , wherein the biological sample comprises a mammary tissue sample.
15. The method of claim 11 , wherein the first detection reagent comprises an antibody that binds to the p16 protein, and wherein the second detection reagent comprises an antibody that binds to the Ki67 protein.
16. The method of claim 11 , wherein the first detection reagent comprises an antibody that binds to the p16 protein, wherein the second detection reagent comprises an antibody that binds to the Ki67 protein, and wherein the third detection reagent comprises an antibody that binds to the COX-2 protein.
17. The method of claim 11 , wherein the first detection reagent comprises an antibody that binds to the p16 protein, and wherein the third detection reagent comprises an antibody that binds to the COX-2 protein.
18. The method of claim 11 , wherein the second detection reagent comprises an antibody that binds to the Ki67 protein, and wherein the third detection reagent comprises an antibody that binds to the COX-2 protein.
19. The method of claim 11 , wherein the at least three detection reagents consist essentially of the first, second and third detection reagents.
20. The method of claim 11 , wherein the at least three detection reagents consist of the first, second and third detection reagents.
21. A method of treating a subject having DCIS, the method comprising administering a treatment to a subject having DCIS and determined to have a mammary epithelial cell signature comprising an elevated level of expression of each of p16, Ki67, and COX-2 compared to respective control levels of expression of p16, Ki67, and COX-2, wherein the treatment comprises: a) a lumpectomy with an additional therapy; or b) a mastectomy.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jun 8, 2023
From: TLSTY, THEA D.; BERMAN, HAL K.; GAUTHIER, MONA L.; LIU, BOB Y.; FORDYCE, COLLEEN A.; PICKERING, CURTIS R.; REYNOLDS, PAUL A.; DUMONT, NANCY; BENTON, GEOFFREY M.
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 063896/0156 →
Continuity (4)
Continuation
12373047
Provisional Application
60830960
· Jul 14, 2006
References Cited (400)
US 4318846A
· Khanna et al.
· 1982
[cited by applicant]
US 4415732A
· Caruthers et al.
· 1983
[cited by applicant]
US 4458066A
· Caruthers et al.
· 1984
[cited by applicant]
US 4591570A
· Chang
· 1986
[cited by applicant]
US 4605735A
· Miyoshi et al.
· 1986
[cited by applicant]
US 4683195A
· Mullis et al.
· 1987
[cited by applicant]
US 4683202A
· Mullis
· 1987
[cited by applicant]
US 4757141A
· Fung et al.
· 1988
[cited by applicant]
US 4889818A
· Gelfand et al.
· 1989
[cited by applicant]
US 4947210A
· Nagata et al.
· 1990
[cited by applicant]
US 5091652A
· Mathies et al.
· 1992
[cited by applicant]
US 5143854A
· Pirrung et al.
· 1992
[cited by applicant]
US 5171695A
· Ekins
· 1992
[cited by applicant]
US 5185439A
· Arnold, Jr. et al.
· 1993
[cited by applicant]
US 5223409A
· Ladner et al.
· 1993
[cited by applicant]
US 5242828A
· Bergstrom et al.
· 1993
[cited by applicant]
US 5283174A
· Arnold et al.
· 1994
[cited by applicant]
US 5288644A
· Fodor et al.
· 1994
[cited by applicant]
US 5292658A
· Cormier et al.
· 1994
[cited by applicant]
US 5313264A
· Ivarsson et al.
· 1994
[cited by applicant]
US 5322770A
· Gelfand
· 1994
[cited by applicant]
US 5324633A
· Fodor et al.
· 1994
[cited by applicant]
US 5399491A
· Kacian et al.
· 1995
[cited by applicant]
US 5403484A
· Ladner et al.
· 1995
[cited by applicant]
US 5409818A
· Davey et al.
· 1995
[cited by applicant]
US 5418144A
· Cormier et al.
· 1995
[cited by applicant]
US 5432049A
· Fischer et al.
· 1995
[cited by applicant]
US 5445934A
· Fodor et al.
· 1995
[cited by applicant]
US 5470710A
· Weiss et al.
· 1995
[cited by applicant]
US 5486452A
· Gordon et al.
· 1996
[cited by applicant]
US 5492806A
· Drmanac et al.
· 1996
[cited by applicant]
US 5498538A
· Kay et al.
· 1996
[cited by applicant]
US 5503980A
· Cantor
· 1996
[cited by applicant]
US 5510270A
· Fodor et al.
· 1996
[cited by applicant]
US 5516637A
· Huang et al.
· 1996
[cited by applicant]
US 5525464A
· Drmanac et al.
· 1996
[cited by applicant]
US 5532128A
· Eggers et al.
· 1996
[cited by applicant]
US 5538848A
· Livak et al.
· 1996
[cited by applicant]
US 5545531A
· Rava et al.
· 1996
[cited by applicant]
US 5547732A
· Edwards et al.
· 1996
[cited by applicant]
US 5547839A
· Dower et al.
· 1996
[cited by applicant]
US 5554517A
· Davey et al.
· 1996
[cited by applicant]
US 5556752A
· Lockhart et al.
· 1996
[cited by applicant]
US 5571698A
· Ladner et al.
· 1996
[cited by applicant]
US 5578832A
· Trulson et al.
· 1996
[cited by applicant]
US 5580732A
· Grossman et al.
· 1996
[cited by applicant]
US 5585481A
· Arnold, Jr. et al.
· 1996
[cited by applicant]
US 5593839A
· Hubbell et al.
· 1997
[cited by applicant]
US 5599695A
· Pease et al.
· 1997
[cited by applicant]
US 5625033A
· Kay et al.
· 1997
[cited by applicant]
US 5631734A
· Stern et al.
· 1997
[cited by applicant]
US 5648211A
· Fraiser et al.
· 1997
[cited by applicant]
US 5658727A
· Barbas et al.
· 1997
[cited by applicant]
US 5661028A
· Foote
· 1997
[cited by applicant]
US 5667988A
· Barbas et al.
· 1997
[cited by applicant]
US 5683888A
· Campbell
· 1997
[cited by applicant]
US 5723591A
· Livak et al.
· 1998
[cited by applicant]
US 5736330A
· Fulton
· 1998
[cited by applicant]
US 5741668A
· Ward et al.
· 1998
[cited by applicant]
US 5744312A
· Mamone et al.
· 1998
[cited by applicant]
US 5760951A
· Dixon et al.
· 1998
[cited by applicant]
US 5777079A
· Tsien et al.
· 1998
[cited by applicant]
US 5786146A
· Herman et al.
· 1998
[cited by applicant]
US 5800992A
· Fodor et al.
· 1998
[cited by applicant]
US 5804387A
· Cormack et al.
· 1998
[cited by applicant]
US 5807522A
· Brown et al.
· 1998
[cited by applicant]
US 5849481A
· Urdea et al.
· 1998
[cited by applicant]
US 5851829A
· Marasco et al.
· 1998
[cited by applicant]
US 5874304A
· Zolotukhin et al.
· 1999
[cited by applicant]
US 5876146A
· Deaver et al.
· 1999
[cited by applicant]
US 5876930A
· Livak et al.
· 1999
[cited by applicant]
US 5876995A
· Bryan
· 1999
[cited by applicant]
US 5904915A
· Fujibayashi et al.
· 1999
[cited by applicant]
US 5925558A
· Tsien et al.
· 1999
[cited by applicant]
US 5948899A
· Arnold et al.
· 1999
[cited by applicant]
US 5965371A
· Marasco et al.
· 1999
[cited by applicant]
US 5981180A
· Chandler
· 1999
[cited by applicant]
US 6004745A
· Arnold et al.
· 1999
[cited by applicant]
US 6007996A
· McNamara et al.
· 1999
[cited by applicant]
US 6057107A
· Fulton
· 2000
[cited by applicant]
US 6063603A
· Davey et al.
· 2000
[cited by applicant]
US 6171797B1
· Perbost
· 2001
[cited by applicant]
US 6180351B1
· Cattell
· 2001
[cited by applicant]
US 6197599B1
· Chin et al.
· 2001
[cited by applicant]
US 6225047B1
· Hutchens et al.
· 2001
[cited by applicant]
US 6232072B1
· Fisher
· 2001
[cited by applicant]
US 6242266B1
· Schleifer et al.
· 2001
[cited by applicant]
US 6320196B1
· Dorsel et al.
· 2001
[cited by applicant]
US 6323043B1
· Caren et al.
· 2001
[cited by applicant]
US 6329209B1
· Wagner et al.
· 2001
[cited by applicant]
US 6331393B1
· Laird et al.
· 2001
[cited by applicant]
US 6355934B1
· Osgood et al.
· 2002
[cited by applicant]
US 6579684B2
· Price et al.
· 2003
[cited by applicant]
US 6610484B1
· Hung
· 2003
[cited by applicant]
US 6797393B2
· Qiao et al.
· 2004
[cited by applicant]
US 6919211B1
· Fodor et al.
· 2005
[cited by applicant]
US 7011949B2
· Amorese et al.
· 2006
[cited by applicant]
US 7081340B2
· Baker
· 2006
[cited by examiner]
US 7112404B2
· Laird et al.
· 2006
[cited by applicant]
US 7186512B2
· Martienssen et al.
· 2007
[cited by applicant]
US 7446185B2
· Nelson
· 2008
[cited by applicant]
US 7452727B2
· Henning et al.
· 2008
[cited by applicant]
US 20030225529A1
· Ecker et al.
· 2003
[cited by applicant]
US 20060063190A1
· Fischer et al.
· 2006
[cited by applicant]
US 20060275844A1
· Linke et al.
· 2006
[cited by applicant]
US 20070077582A1
· Slepnev
· 2007
[cited by applicant]
US 20070105133A1
· Clarke et al.
· 2007
[cited by applicant]
US 20100003189A1
· Tlsty et al.
· 2010
[cited by applicant]
US 20100068717A1
· Badve et al.
· 2010
[cited by applicant]
US 20100158894A1
· Umemura
· 2010
[cited by applicant]
US 20130317083A1
· Rigoutsos
· 2013
[cited by applicant]
US 20170184601A1
· Tlsty et al.
· 2017
[cited by applicant]
US 20220187301A1
· Bremer
· 2022
[cited by applicant]
AU 20072763055
· 2008
[cited by applicant]
AU 2011248632
· 2012
[cited by applicant]
AU 2013205536
· 2013
[cited by applicant]
AU 2013205531
· 2016
[cited by applicant]
CA 2657576
· 2008
[cited by applicant]
EP 0244210
· 1989
[cited by applicant]
EP 0204157
· 1990
[cited by applicant]
EP 0245071
· 1992
[cited by applicant]
EP 0329822
· 1994
[cited by applicant]
EP 0373203
· 1994
[cited by applicant]
EP 0721016
· 1996
[cited by applicant]
EP 0728520
· 2001
[cited by applicant]
EP 0785280
· 2003
[cited by applicant]
EP 0799897
· 2006
[cited by applicant]
EP 2041574
· 2009
[cited by applicant]
EP 2442108
· 2012
[cited by applicant]
EP 2442109
· 2012
[cited by applicant]
EP 2450710
· 2012
[cited by applicant]
EP 2564200
· 2013
[cited by applicant]
EP 3227687
· 2017
[cited by applicant]
EP 3508854
· 2019
[cited by applicant]
WO WO199102814
· 1991
[cited by applicant]
WO WO199215673
· 1992
[cited by applicant]
WO WO199500669
· 1995
[cited by applicant]
WO WO199507463
· 1995
[cited by applicant]
WO WO199521265
· 1995
[cited by applicant]
WO WO199522058
· 1995
[cited by applicant]
WO WO199535505
· 1995
[cited by applicant]
WO WO199631622
· 1996
[cited by applicant]
WO WO199702357
· 1997
[cited by applicant]
WO WO199710365
· 1997
[cited by applicant]
WO WO199727317
· 1997
[cited by applicant]
WO WO1997292212
· 1997
[cited by applicant]
WO WO199814605
· 1998
[cited by applicant]
WO WO199826277
· 1998
[cited by applicant]
WO WO199939210
· 1999
[cited by applicant]
WO WO199949019
· 1999
[cited by applicant]
WO WO199951773
· 1999
[cited by applicant]
WO WO200004382
· 2000
[cited by applicant]
WO WO200004389
· 2000
[cited by applicant]
WO WO200004390
· 2000
[cited by applicant]
WO WO200054046
· 2000
[cited by applicant]
WO WO200056934
· 2000
[cited by applicant]
WO WO200114425
· 2001
[cited by applicant]
WO WO200140803
· 2001
[cited by applicant]
WO WO2002019767
· 2002
[cited by applicant]
WO WO200063701
· 2002
[cited by applicant]
WO WO2005038051
· 2005
[cited by applicant]
WO WO2005083429
· 2005
[cited by applicant]
WO WO2008008284
· 2008
[cited by applicant]
WO WO2011139721
· 2011
[cited by applicant]
WO WO2016090323
· 2016
[cited by applicant]
WO WO2020056338
· 2020
[cited by applicant]
U.S. Appl. No. 17/652,466, filed Feb. 24, 2022, Bremer.
[cited by applicant]
Allred et al., “Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: A study based on NSABP protocol B-24”. J Clin Oncol. 2012; vol. 30, No. 12, pp. 1268…
[cited by applicant]
Breastcancer.org, “New Guidelines Say Lumpectomy Margins Can Be Small as Long as Tumor Has No Ink on It”. 2 pages; (Mar. 12, 2018) available at https://www.breastcancer.org/research-news/20140402. This reference is a we…
[cited by applicant]
Chivukula et al., “Ductal Carcinoma In Situ: One Size Does Not Fit All”. Women's Health. Sep. 2010:669-672.
[cited by applicant]
Cuzick et al., Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial, The Lancet Oncology, vol. 12, Issue 1, pp. 21-29, 2011.
[cited by applicant]
Declaration By Troy Bremer in U.S. Appl. No. 15/529,966, filed Feb. 2, 2021.
[cited by applicant]
Fisher et al., “Prevention of invasive breast cancer in women with ductal carcinoma in situ: An update of the National Surgical Adjuvant Breast and Bowel Project experience”. Semin Oncol., Aug. 1, 2001; vol. 28, No. 4, …
[cited by applicant]
Lari et al., “Biological Markers in DCIS and Risk of Breast Recurrence: A Systematic Review”. J Cancer, 2011: vol. 2, pp. 232-261.
[cited by applicant]
Marsh K. et al., “Frequent Alterations of Cell Cycle Regulators in Early-Stage Breast Lesions as Detected By Immunohistochemistry”. Br J Cancer, 1998; vol. 77, No. 9, pp. 1460-1468.
[cited by applicant]
Picarsic et al., Predictors of invasive breast cancer or DCIS recurrence in estrogen receptor positive (ER+) and estrogen receptor negative (ER−) ductal carcinoma in situ (DCIS) patients with and without associated inva…
[cited by applicant]
Picarsic et al., Role of Transcription Factors [FOXA1,GATA-3] in Predicting Outcomes in Recurrent Ductal Carcinoma-In-Situ (DCIS) or Invasive Carcinoma (IC) in DCIS Patients on Core Needle Biopsies of Breast. Cancer Res…
[cited by applicant]
Siewertsz van Reesema L. et al., “SIAH and EGFR; Two RAS Pathway Biomarkers are Highly Prognostic in Locally Advanced and Metastatic Breast Cancer”. EBioMedicine. Sep. 1, 2016;11: 183-198.
[cited by applicant]
Solin, L. J. et al., “A Multigene Expression Assay to Predict Local Recurrence Risk for Ductal Carcinoma In Situ of the Breast”. J Nat Cancer Inst., May 15, 2013; 105(10): 701-710.
[cited by applicant]
Vicini et al., “Biosignatures to Optimize Adjuvant Radiation Therapy Use in Patients with DCIS with High Risk Clinicopathologic Features”. American Society of Radiation Oncology Annual Meeting 2021, 2 pages.
[cited by applicant]
Wärnberg et al., “Abstract GS5-08: A Validation of DCIS Biiological Risk Profile in a Randomised Study for Radiation Therapy with 20 Year Follow-up (SweDCIS)”. Cancer Res. Feb. 15, 2018; Abstract.
[cited by applicant]
Yang M. et al., “Microinvasive ductal carcinoma {T1 mic) of the breast. The clinicopathological profile and immunohistochemical features of 28 cases”. Pathol Inter'l. 2003; vol. 53, pp. 422-428.
[cited by applicant]
Response to U.S. Office Action dated Sep. 24, 2014, filed Mar. 23, 2015 in U.S. Appl. No. 12/373,047.
[cited by applicant]
Response to U.S. Office Action dated May 29, 2015, filed Nov. 20, 2015 in U.S. Appl. No. 12/373,047.
[cited by applicant]
Response to U.S. Office Action dated Mar. 11, 2022, filed Aug. 5, 2022 in U.S. Appl. No. 15/284,349.
[cited by applicant]
U.S. Office Action dated Apr. 11, 2014 in U.S. Appl. No. 13/094,729.
[cited by applicant]
Response (Supplemental) to Office Action dated Jul. 23, 2015, filed on Apr. 14, 2016 in U.S. Appl. No. 13/094,729.
[cited by applicant]
U.S. Office Action dated Jan. 18, 2022, received in U.S. Appl. No. 13/094,729.
[cited by applicant]
Response to Office Action dated Jan. 18, 2022, filed Jun. 21, 2022 in U.S. Appl. No. 13/094,729.
[cited by applicant]
U.S. Office Action dated Aug. 15, 2022, received in U.S. Appl. No. 13/094,729.
[cited by applicant]
Response to U.S. Office Action dated Dec. 7, 2021, filed Feb. 9, 2022 in U.S. Appl. No. 15/529,966.
[cited by applicant]
U.S. Office Action dated Mar. 1, 2022 in U.S. Appl. No. 15/529,966.
[cited by applicant]
Response to U.S. Office Action dated Mar. 1, 2022 filed Aug. 25, 2022 in U.S. Appl. No. 15/529,966.
[cited by applicant]
U.S. Office Action dated Jun. 14, 2022 in U.S. Appl. No. 17/652,471.
[cited by applicant]
Response to Restriction Requirement dated Jun. 14, 2022, filed Aug. 10, 2022 in U.S. Appl. No. 17/652,471.
[cited by applicant]
U.S. Office Action dated Aug. 30, 2022 in U.S. Appl. No. 17/652,471.
[cited by applicant]
Canadian Office Action dated May 2, 2022 in CA Application No. 2657576.
[cited by applicant]
Response to European Office Action dated Jul. 18, 2011, filed Jan. 26, 2012 in EP Application No. 07810252.2.
[cited by applicant]
Response to European Office Action dated Aug. 11, 2014, filed May 20, 2015 in EP Application No. 07810252.2.
[cited by applicant]
Response to European Search Report dated Jun. 27, 2012, filed Jan. 24, 2013 in EP Application No. 11188923.4.
[cited by applicant]
Response to Office Action dated Feb. 18, 2013, filed Aug. 26, 2013 in EP Application No. 11188923.4.
[cited by applicant]
Response to European Office Action dated Jul. 15, 2014, filed Apr. 29, 2015 in EP Application No. 11188923.4.
[cited by applicant]
Response to European Office Action dated May 18, 2015, filed Sep. 18, 2015 in EP Application No. 11188923.4.
[cited by applicant]
Response to European Office Action dated May 12, 2016, filed Nov. 22, 2016 in EP Application No. 11188923.4.
[cited by applicant]
Response to European Office Action dated Jun. 12, 2017, filed Oct. 17, 2017 in EP Application No. 11188923.4.
[cited by applicant]
Response to European Office Action dated Feb. 23, 2018, filed Sep. 4, 2018 in EP Application No. 11188923.4.
[cited by applicant]
Response to European Office Action dated Nov. 29, 2018, filed Apr. 9, 2019 in EP Application No. 11188923.4.
[cited by applicant]
Response to European Office Action dated Sep. 16, 2019, filed Jan. 21, 2020 in EP Application No. 11188923.4.
[cited by applicant]
Response to Extended Search Report dated Mar. 20, 2012, filed Februay 7, 2013 in EP Application No. 11188925.9.
[cited by applicant]
Response to European Office Action dated Mar. 4, 2013, filed Sep. 13, 2013 in EP Application No. 11188925.9.
[cited by applicant]
Response to Extended Search Report dated Mar. 20, 2012, filed Februay 7, 2013 in EP Application No. 11188926.7.
[cited by applicant]
Response to European Office Action dated Mar. 4, 2013, filed Sep. 13, 2013 in European Application No. 11188926.7.
[cited by applicant]
Response to European Office Action dated Sep. 26, 2013, filed Jul. 2, 2014 in EP Application No. 11188926.7.
[cited by applicant]
European Office Action dated Apr. 13, 2022 in EP Application No. 20190672.4.
[cited by applicant]
Partial European Search Report dated Jun. 30, 2022 in EP Application No. EP 19859855.9.
[cited by applicant]
Response to Japanese Office Action dated Apr. 8, 2014, filed Jul. 8, 2014 in JP Application No. 2009- 520751.
[cited by applicant]
File History, U.S. Appl. No. 13/094,729, filed Apr. 26, 2011.
[cited by applicant]
File History, U.S. Appl. No. 17/275,406, filed Mar. 11, 2021.
[cited by applicant]
File History, U.S. Appl. No. 17/652,471, filed Feb. 24, 2021.
[cited by applicant]
Bouvier-Labit, C., et al., “P16 and P19 MRNA expression in neuroglial tumours: Correlation with KI67 proliferation index, neuropathology and applied neurobiology,” 1999, vol. 25, pp. 408-416.
[cited by applicant]
Canadian Office Action dated May 1, 2020, in Canadian Application 2,797,585.
[cited by applicant]
Darling, Maria L. Rosenfield et al., “Atypical ductal hyperplasia and ductal carcinoma in situ as revealed by large-core needle breast biopsy: Results of surgical excision,” American Journal of Roentgenology, 2000, vol.…
[cited by applicant]
Response to European Office Action Response filed Apr. 23, 2019 in European Patent Application No. EP15865163.8.
[cited by applicant]
Response to U.S. Office Action filed Jun. 28, 2019 in U.S. Appl. No. 15/529,966.
[cited by applicant]
Response to U.S Office Action filed Oct. 17, 2019 in U.S. Appl. No. 15/529,966.
[cited by applicant]
Wiechmann. L et al., “The molecular journey from ductal carcinoma in situ to invasive breast cancer,” American Cancer Society, 2008, vol. 112, pp. 2130-2142.
[cited by applicant]
Zhou et al., “Tumor Markers Predicting Recurrence Type after a Primary Ductal Carcinoma In Situ”, Cancer Research, vol. 71, No. 24, P4-10-01, Dec. 1, 2012, XP055643824.
[cited by applicant]
Zhou et al., “A Comparison of Tumor Biology in Primary Ductal Carcinoma In Situ Recurring as Invasive Carcinoma versus a New In Situ”, International Journal of Breast Cancer, vol. 2013, Jan. 1, 2013, pp. 1-8, XP05564382…
[cited by applicant]
Response to Canadian Office Action dated (Dec. 15, 2014), filed Jun. 10, 2015 received in Canadian Appl. No. 2,657,576.
[cited by applicant]
Response to Canadian Office Action dated (Dec. 19, 2016), filed Feb. 24, 2017 received in Canadian Appl. No. 2,657,576.
[cited by applicant]
Response to Canadian Office Action dated (Jun. 21, 2017), filed Dec. 19, 2017 received in Canadian Appl. No.2,657,576.
[cited by applicant]
Response to Canadian Office Action dated (May 31, 2018), filed Nov. 27, 2019 in Canadian Patent Application Np. 2,657,576.
[cited by applicant]
Response to Canadian Office Action dated (Apr. 21, 2017), filed Oct. 20, 2017 Canadian Application No. 2,797,585.
[cited by applicant]
Response to Canadian Office Action dated (Dec. 1, 2017), filed Jun. 1, 2018 in Canadian Application 2,797, 585.
[cited by applicant]
Response to Canadian Office Action dated (Jun. 7, 2019), filed Dec. 9, 2019 in Canadian Application 2,797,585.
[cited by applicant]
Response to Canadian Office Action dated (May 1, 2020), filed Nov. 2, 2020 in Canadian Application 2,797,585.
[cited by applicant]
Declaration by Troy Bremer and Exhibits (A-G) in U.S. Appl. No. 13/094,729, dated Nov. 9, 2020.
[cited by applicant]
Notice of Allowance in U.S. Appl. No. 15/529,966, dated Jun. 1, 2021.
[cited by applicant]
Response to Office Action dated Dec. 21, 2020 Response Filed Jan. 18, 2021 in European Patent Application No. EP 15865163.8.
[cited by applicant]
U.S. Office Action dated Jun. 22, 2020 in U.S. Appl. No. 15/529,966.
[cited by applicant]
U.S. Office Action dated Mar. 2, 2020 in U.S. Appl. No. 15/529,966.
[cited by applicant]
Response to Office Action dated Mar. 15, 2021 filed on Jun. 14, 2021 in U.S. Appl. No. 13/094,729.
[cited by applicant]
Final Office Action dated Mar. 15, 2021 in U.S. Appl. No. 13/094,729.
[cited by applicant]
European Office Action dated Jun. 11, 2021 in European Patent Application No. 18209239.5.
[cited by applicant]
Office Action Response filed on Feb. 22, 2018 in U.S. Appl. No. 15/529,966 in 11 pages.
[cited by applicant]
Office Action Response filed on Aug. 16, 2018 in U.S. Appl. No. 15/529,966 in 15 pages.
[cited by applicant]
Office Action Response filed on May 29, 2020 in U.S. Appl. No. 15/529,966 in 15 pages.
[cited by applicant]
Office Action Response filed on Feb. 3, 2021 in U.S. Appl. No. 15/529,966 in 19 pages.
[cited by applicant]
Response to European Office Action filed May 28, 2020 in European Patent Application No. EP15865163.8.
[cited by applicant]
Response to Office Action (dated Nov. 10, 2014) Filed Jul. 19, 2016, in Australian Patent Application No. 2013205531.
[cited by applicant]
Canadian Office Action dated Dec. 9, 2015, received in Canadian Appl. No. 2,657,576.
[cited by applicant]
Response to Canadian Office Action dated (Dec. 9, 2015), filed Jun. 9, 2016 received in Canadian Appl. No. 2,657,576.
[cited by applicant]
Canadian Office Action dated Jun. 30, 2020, received in Canadian Appl. No. 2,657,576.
[cited by applicant]
Canadian Office Action dated Jun. 14, 2021, received in Canadian Appl. No. 2,657,576.
[cited by applicant]
Response to Office Action dated Sep. 17, 2013 filed on Mar. 14, 2014 in U.S. Appl. No. 13/094,729.
[cited by applicant]
Response to Office Action dated Apr. 11, 2014 filed on Jul. 11, 2014 in U.S. Appl. No. 13/094,729.
[cited by applicant]
Response to Office Action dated Jul. 23, 2015 filed on Jan. 21, 2016 in U.S. Appl. No. 13/094,729.
[cited by applicant]
Response to Office Action dated Apr. 27, 2016 filed on Sep. 27, 2016 in U.S. Appl. No. 13/094,729.
[cited by applicant]
Response to Office Action dated Dec. 5, 2017 filed on Mar. 6, 2017 in U.S. Appl. No. 13/094,729.
[cited by applicant]
Response to Office Action dated Mar. 24, 2017 filed on Jun. 26, 2017 in U.S. Appl. No. 13/094,729.
[cited by applicant]
Response to Office Action dated Mar. 16, 2018 filed on Jun. 14, 2018 in U.S. Appl. No. 13/094,729.
[cited by applicant]
Response to Office Action dated Sep. 26, 2018 filed on Feb. 25, 2019 in U.S. Appl. No. 13/094,729.
[cited by applicant]
Response to Office Action dated Mar. 29, 2019 filed on Jul. 1, 2019 in U.S. Appl. No. 13/094,729.
[cited by applicant]
Response to Office Action dated Oct. 8, 2019 filed on Feb. 11, 2020 in U.S. Appl. No. 13/094,729.
[cited by applicant]
U.S. Office Action dated Jun. 8, 2020, received in U.S. Appl. No. 13/094,729.
[cited by applicant]
Response to Office Action dated Jun. 8, 2020 filed on Nov. 9, 2020 in U.S. Appl. No. 13/094,729.
[cited by applicant]
Response to Australian Office Action dated Sep. 19, 2013 filed on Jun. 3, 2015 in Australian Application No. 2011248632.
[cited by applicant]
Canadian Office Action dated Dec. 1, 2017, Canadian Application No. 2,797,585.
[cited by applicant]
Response to Canadian Office Action dated Dec. 1, 2017, Filed Jun. 12, 2018, Canadian Application No. 2,797,585.
[cited by applicant]
Canadian Office Action dated Jun. 7, 2019, Canadian Application No. 2,797,585.
[cited by applicant]
Response to Canadian Office Action dated Jun. 7, 2019, Filed Dec. 9, 2019 Canadian Application No. 2,797,585.
[cited by applicant]
Response to European Office Action dated Sep. 30, 2014, Filed Aug. 16, 2016 European Application No. 11721599.6.
[cited by applicant]
Response to European Office Action dated Mar. 6, 2017, Filed Jul. 4, 2017 European Application No. 11721599.6.
[cited by applicant]
Response to European Office Action dated Apr. 19, 2018, Filed Jun. 18, 2018 European Application No. 11721599.6.
[cited by applicant]
Office Action dated Aug. 3, 2021 received in U.S. Appl. No. 13/094,729 in 32 pages.
[cited by applicant]
Canadian Office Action dated Apr. 7, 2021 Canadian Application No. 2,797,585.
[cited by applicant]
Wood, The Role of Clinical Trials in Changing Therapy for Ductal Carcinoma In Situ. Annals of Surgical Oncology, 2004; 11 (1 ):24S-27S. (Year: 2004).
[cited by applicant]
Boughey et al. Current Treatment and Clinical Trial Developments for Ductal Carcinoma In Situ of the Breast Boughey et al. The Oncologist; 2007;12:1276-1287. (Year: 2007).
[cited by applicant]
Response to Canadian Office Action dated Apr. 7, 2021, Filed Oct. 7, 2021, Canadian Application No. 2,797,585.
[cited by applicant]
Response to Canadian Office Action dated Jun. 14, 2021, filed Nov. 8, 2021 in Canadian Appl. No. 2,657,576.
[cited by applicant]
Response to Office Action dated Jan. 29, 2021 filed on Dec. 10, 2021 in European Patent Application No. 20190672.4 in 5 pages.
[cited by applicant]
Response to Office Action dated Aug. 3, 2021 filed on Dec. 2, 2021 in U.S. Appl. No. 13/094,729.
[cited by applicant]
Office Action dated Dec. 7, 2021 in U.S. Appl. No. 15/529,966.
[cited by applicant]
Response to European Search Reported dated Mar. 19, 2019 filed on Jan. 9, 2020 in European Patent Application No. 18209239.5.
[cited by applicant]
Response to Office Action dated Jun. 11, 2021 filed Dec. 8, 2021 in European Patent Application No. 18209239.5.
[cited by applicant]
Dunne et al., Effect of Margin Status on Local Recurrence After Breast Conservation and Radiation Therapy for Ductal Carcinoma In Situ, Journal of Clinical Oncology, vol. 27, No. 10, 2009.
[cited by applicant]
Office Action Response filed on Oct. 30, 2020 in Canadian Patent Application No. 2657576 in 63 pages.
[cited by applicant]
Office Action Response filed on Dec. 10, 2020 in Canadian Patent Application No. 2797585 in 46 pages.
[cited by applicant]
Office Action dated Dec. 21, 2020 received in European Patent Application No. EP15865163.8 in 3 pages.
[cited by applicant]
Office Action Response Filed Jan. 18, 2021 in European Patent Application No. EP15865163.8 in 3 pages.
[cited by applicant]
Office Action dated Jan. 29, 2021 received in European Patent Application No. 20190672.4 in 9 pages.
[cited by applicant]
Office Action Response and declaration filed on Feb. 3, 2021 in U.S. Appl. No. 15/529,966 in 23 pages.
[cited by applicant]
Office Action dated Mar. 15, 2021 received in U.S. Appl. No. 13/094,729 in 32 pages.
[cited by applicant]
Office Action Response and declaration filed on Nov. 9, 2020 in U.S. Appl. No. 13/094,729 in 21 pages.
[cited by applicant]
Affymetrix Solutions for Cancer Analysis Data Sheet, dated 2005.
[cited by applicant]
Boland (British Journal of Cancer 2004 vol. 90 pp. 423-429) (Year: 2004).
[cited by applicant]
Burstein (The New England Journal of Medicine vol. 350 No 14 pp. 1430-1441 2004) (Year: 2004).
[cited by applicant]
Cheng et al (Journal of the National Cancer Institute, 1997, 89: 1356-1360).
[cited by applicant]
Ernster et al., “Detection of DCIS in women undergoing screening Mammography”, J. Natl Cancer vol. 94 No. 20, pp. 1546-1954 (2002).
[cited by applicant]
European Office Action dated Aug. 5, 2009 in corresponding European Patent Application No. 07810252.2.
[cited by applicant]
European Office Action dated Nov. 25, 2019 in European Application No. 15 865 163.8.
[cited by applicant]
European Search Report dated Mar. 19, 2019 in European Patent Application No. 18209239.5.
[cited by applicant]
Extended European Search Report dated Sep. 21, 2018 in European Patent Application No. 15865163.8.
[cited by applicant]
International Search Report dated Sep. 19, 2008 in International Application No. PCT-US07/15584.
[cited by applicant]
International Search report and written opinion dated Dec. 5, 2019 in international application No. PCT/US19/51128.
[cited by applicant]
March (British Journal of Cancer 1998 vol. 77 No 9 pp. 1460-1468) (Year: 1998).
[cited by applicant]
Marsh, KL et al., “Loss of heterozygosity at chromosome 9p in ductal carcinoma in situ and invasive carcinoma of the breast,” British Journal of Cancer, 1998, vol. 77, No. 9, pp. 1439-1447.
[cited by applicant]
Mohsin (Modern Pathology 2004 vol. 17 pp. 1545-1554) (Year: 2004).
[cited by applicant]
Office Action dated Nov. 10, 2014 in Australian Patent Application No. 2013205531.
[cited by applicant]
Office Action dated Nov. 10, 2014 in Australian Patent Application No. 2013205536.
[cited by applicant]
Office Action dated Feb. 23, 2018 in European Patent Application No. 11188923.4.
[cited by applicant]
Prelude Press Release dated Aug. 2, 2018 entitled Journal of Clinical Cancer Res arch Publication Demonstrates that DCISionRT® Provides Prognostic and Predictive Power for Assessing a Patient's DCIS Risk.
[cited by applicant]
Response to Office Action (dated Jun. 23, 2011) filed Sep. 23, 2011 in U.S. Appl. No. 12/373,047.
[cited by applicant]
Response to US Office Action (dated Apr. 10, 2012) filed Jul. 9, 2012 in related U.S. Appl. No. 12/373,047.
[cited by applicant]
Response to Australian Office Action (dated Jul. 25, 2012) filed Mar. 14, 2014 in corresponding Australian Application No. 2007273055.
[cited by applicant]
Response to Australian Office Action (dated Mar. 25, 2014) filed Apr. 9, 2014 in corresponding Australian Application No. 2007273055.
[cited by applicant]
Response to Canadian Office Action (dated Nov. 20, 2013) filed May 20, 2014 in corresponding Canadian Application No. 2657576.
[cited by applicant]
Response to European Office Action (dated Aug. 5, 2009) filed May 17, 2010 in corresponding European Application No. 07810252.2.
[cited by applicant]
Response to European Office Action (dated May 31, 2010) filed Nov. 25, 2010 in corresponding European Application No. 07810252.2.
[cited by applicant]
Response to European Office Action (dated Dec. 8, 2010) filed Jun. 14, 2011 in corresponding European Application No. 07810252.2.
[cited by applicant]
Response to European Office Action (dated Sep. 20, 2013) filed Jun. 30, 2014 in corresponding European Application No. 11188923.4.
[cited by applicant]
Response to European Office Action (dated Sep. 26, 2013) filed Jul. 2, 2014 in corresponding European Application No. 11188925.9.
[cited by applicant]
Response to European Office Action (dated Sep. 26, 2013) filed Jul. 2, 2014 in corresponding European Application No. 11188926.7.
[cited by applicant]
Response to Japanese Office Action (dated Jan. 8, 2013) filed Jul. 5, 2013 in corresponding Japanese Application No. 2009-520751.
[cited by applicant]
Response to European Communication pursuant to Rules 161 (1) and 162 EPC (dated Dec. 7, 2012) filed Jun. 5, 2013 in corresponding European Application No. 11721599.6.
[cited by applicant]
Response to U.S. Office Action dated (Apr. 11, 2014), filed Jul. 11, 2014 received in U.S. Appl. No. 13/094,729.
[cited by applicant]
Response to U.S. Office Action dated (Jul. 23, 2015), filed Jan. 21, 2016 in U.S. Appl. No. 13/094,729.
[cited by applicant]
Response to U.S. Office Action dated (Sep. 17, 2013), filed Mar. 14, 2014 received in U.S. Appl. No. 13/094,729.
[cited by applicant]
Response to U.S. Office Action dated (Apr. 27, 2016), filed Sep. 27, 2016 received in U.S. Appl. No. 13/094,729.
[cited by applicant]
Response to U.S. Office Action dated (Dec. 5, 2016), filed Mar. 6, 2017 received in U.S. Appl. No. 13/094,729.
[cited by applicant]
Response to U.S. Office Action dated (Mar. 24, 2017), Filed Jul. 19, 2017, received in U.S. Appl. No. 13/094,729.
[cited by applicant]
Response to U.S. Office Action dated (Mar. 16, 2018), Filed Jun. 14, 2018, in U.S. Appl. No. 13/094,729.
[cited by applicant]
Response to U.S. Office Action dated (Sep. 26, 2018), filed Feb. 25, 2019 in U.S. Appl. No. 13/094,729.
[cited by applicant]
Response to U.S. Office Action dated (Mar. 29, 2019), filed Jul. 1, 2019, in U.S. Appl. No. 13/094,729.
[cited by applicant]
Response to U.S. Office Action dated (Oct. 8, 2019), filed Feb. 11, 2020 in U.S. Appl. No. 13/094,729.
[cited by applicant]
Response to Canadian Office Action dated (Nov. 20, 2013), filed May 20, 2014 received in Canadian Appl. No. 2,657,576.
[cited by applicant]
Salido (Breast Cancer Research 2005 vol. 7 R267-R273) (Year: 2005).
[cited by applicant]
Sendur, et al., Cardiotoxicity of Novel HER2-Targeted Therapies, Current Medical Research and Opinion, vol. 29, No. 8, pp. 1015-1024, 2013.
[cited by applicant]
Steinman (Annals of Clinical and Laboratory Science vol. 37 No. 2 2007 pp. 127-134) (Year: 2007).
[cited by applicant]
Office Action in Canadian Patent Application Np. 2,657,576, dated Jun. 30, 2020.
[cited by applicant]
Office Action in Canadian Application 2,797,585, dated May 1, 2020.
[cited by applicant]
Office Action in U.S. Appl. No. 13/094,729, dated Jun. 8, 2020.
[cited by applicant]
Office Action in U.S. Appl. No. 15/529,966, dated Jun. 22, 2020.
[cited by applicant]
Response to Office Action in European Patent Application No. EP15865163.8, filed May 28, 2020.
[cited by applicant]
Response to European Search Report dated Mar. 19, 2019 in European Patent Application No. 18209239.5, filed Jan. 9, 2020.
[cited by applicant]
Response to Office Action dated Sep. 16, 2019 in European Patent Application No. 1188923.4, filed Jan. 21, 2020.
[cited by applicant]
Office Action dated Sep. 16, 2019 in European Application No. 11188923.4.
[cited by applicant]
Office Action dated Oct. 8, 2019 in U.S. Appl. No. 13/094,729.
[cited by applicant]
Office Action dated Jun. 7, 2019 in Canadian Application No. 2797585.
[cited by applicant]
Office Action dated Jul. 17, 2019 in U.S. Appl. No. 15/529,966.
[cited by applicant]
Dedeoǧlu, Analysis of Differentially expressed genes in breast Cancer: brca1-induced gene expression Profiles and meta- analysis gene Signature, Thesis Submitted to Bilkent University, (2009).
[cited by applicant]
European Search Reported dated Mar. 13, 2019 in European Patent Application No. 1820939.5.
[cited by applicant]
Long-Term Results Show that Radiation Therapy After Lumpectomy to Remove DCIS Reduces Recurrence Risk, Published Oct. 4, 2013 < https://www.breastcancer.org/research-news/20131004> Applicants note that the webpage was p…
[cited by applicant]
Older Women Diagnosed with DCIS or Early-Stage Disease Have Excellent Prognosis, Published Mar. 16, 2011 < https://www.breastcancer.org/research-news/20110316> Applicants note that the webpage was printed on Mar. 12, 20…
[cited by applicant]
Office Action dated May 31, 2018 in Canadian Patent Application Np. 2,657,576.
[cited by applicant]
Office Action dated Sep. 26, 2018 in U.S. Appl. No. 13/094,729.
[cited by applicant]
Office Action dated Nov. 29, 2018 in European Patent Application No. 1188923.4.
[cited by applicant]
Office Action dated Mar. 18, 2019 in U.S. Appl. No. 15/529,966.
[cited by applicant]
Office Action dated Mar. 29, 2019 in U.S. Appl. No. 13/094,729.
[cited by applicant]
Supplementary European Search Report dated Sep. 21, 2018 in European Patent Application Np: 15865163.8.
[cited by applicant]
Wolf et al., FOXA1: Growth Inhibitor and a Favorable Prognostic Factor in Human Breast Cancer, Int. J. Cancer, vol. 120, pp. 1013-1022, (2006).
[cited by applicant]
File History, U.S. Appl. No. 15/529,966, filed May 25, 2017.
[cited by applicant]
Office Action Dated Apr. 19, 2018 in European Patent Application Np. 11721599.6.
[cited by applicant]
Albergaria, et al. Expression of FOXA1 and GATA-3 in Breast Cancer: The Prognostic Significance in Hormone Receptor-Negative Tumors, Breast Cancer Research, vol. 11 No. 3, pp. 1-15 (2009).
[cited by applicant]
Badve et al., FOXA 1 Expression 1n Breast Cancer Correlation with Luminal Subtype A and 34 Survival, Clin Cancer Res, vol. 13, pp. 4415-4421, Aug. 1, 2007.
[cited by applicant]
Bartova, M, et al., COX-2, p16 and Ki67 Expression in DCIS, Microinvasive and Early Invasive Breast Carcinoma with Extensive Intraductal Component, Bratislava Medical Journal, vol. 115, No. , pp. 445-45, (2014).
[cited by applicant]
Behling, K et al., Increased SIAH Expression Predicts Ductal Carcinoma in situ (DCIS) Progression to Invasive Carcinoma, Breast Cancer Research and Treatment, vol. 129, No. 3, pp. 717-724, (2010).
[cited by applicant]
Chan et al., The expression of the ubiquitin ligase SIAH2 (seven in absentia homolog 2) is mediated through gene copy number in breast cancer and is associated with a basal-like phenotype and p53 expression, Breast Canc…
[cited by applicant]
Crawford et al., “Histologically normal human mammary epithelia with silenced p16(INK4a) overexpress COX-2, promoting a premalignant program,”
[cited by applicant]
Extended European Search Report dated Aug. 5, 2009, received in European Patent Appl. No. 07810252.2.
[cited by applicant]
Gorringe, K, et al. Ductal Carcinoma In Situ Biology, Biomarkers and Diagnosis, Frontiers in Oncology, vol. 7, Article, 248, pp. 1-14, (2017).
[cited by applicant]
Hammond et al., American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer (Unabridged Versio…
[cited by applicant]
Horimoto et al., Low FOXA 1 expression predicts good response to neo-adjuvant chemotherapy resulting in good outcomes for luminal HER2-negative breast cancer cases, British Journal of Cancer, vol. 112, pp. 345-351, Epub…
[cited by applicant]
International Search Report & Written Opinion, dated Feb. 16, 2016, in International Application PCT/US2015/064115.
[cited by applicant]
Kerlikowske et al., “Biomarker Expression and Risk of Subsequent Tumors after Initial Ductal Carcinoma in situ Diagnosis”,
[cited by applicant]
Kerlikowske et al., “Characteristics associated with recurrence among women with ductal carcinoma in situ treated by lumpectomy”,
[cited by applicant]
Lee et al., Context-Specific Regulation of NF-kB Target Gene Expression by EZH2 in Breast Cancers, Mol Cell, vol. 43, pp. 798-810, Sep. 2, 2011.
[cited by applicant]
Muggerud, A., et al., Molecular Diversity in Ductal Carcinoma in situ (DCIS) and Early Invasive Breast Cancer, Molecular Oncology, vol. 4, No. 4, pp. 357-368, (2010).
[cited by applicant]
Office Action dated May 31, 2010, received in European Patent Appl. No. 07810252.2.
[cited by applicant]
Office Action dated Dec. 7, 2012 in European Application No. 11721599.6.
[cited by applicant]
Office Action dated Sep. 19, 2013 in Australian Application No. 2011248632.
[cited by applicant]
Office Action dated Sep. 26, 2013 in European Patent Application No. 11188926.7.
[cited by applicant]
Office Action dated Apr. 8, 2014 in received in Japanese Appl. No. 2009-520751 (with English translation).
[cited by applicant]
Office Action dated Dec. 1, 2017 in Canadian Application 2,797, 585.
[cited by applicant]
Office Action dated Mar. 16, 2018 in U.S. Appl. No. 13/094,729.
[cited by applicant]
Office Action dated Oct. 23, 2017 in U.S. Appl. No. 15/529,966.
[cited by applicant]
Office Action dated Mar. 16, 2018 in U.S. Appl. No. 15/529,966.
[cited by applicant]
Partial European Search Report received in European Patent Application No. EP 11 18 8923, filed Jul. 3, 2007.
[cited by applicant]
Cited By (1)